Research progress of Bruton tyrosine kinase inhibitors in mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2016.06.017
- VernacularTitle:Bruton酪氨酸激酶抑制剂在套细胞淋巴瘤中的研究进展
- Author:
Xiangxiang ZHOU
;
Xin WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,mantle-cell;
Bruton tyrosine kinase inhibitor;
Ibrutinib
- From:
Journal of Leukemia & Lymphoma
2016;25(6):377-380
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma (MCL), is a disease with high heterogeneity, which is insensitivity to the chemotherapy and presents poor prognosis. Appearance of the Bruton tyrosine kinase (BTK) targeted inhibitors, such as ibrutinib, provides novel treatment strategy for MCL. This review focused on the latest achievements of BTK inhibitors in MCL treatment.
